NCT05502991View on ClinicalTrials.gov

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNA-level-relapse and Clinical-relapse Glioblastoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 11, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Glioblastoma
Interventions
DRUG

Tislelizumab plus Bevacizumab

200mg sintilimab plus 3mg/kg bevacizumab every 3 weeks

Trial Locations (1)

450003

Henan Provincial People's Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Provincial People's Hospital

OTHER